For the first time, a Spanish trial developed over 20 years has succeeded in curing Fanconi anemia patients with gene therapy.
Fanconi anemia is a rare genetic disorder affecting bone marrow, characterized by impaired DNA repair mechanisms, causing a progressive loss of all types of blood cells. Likewise, its patients have a high predisposition to develop head and neck tumors at a very early age.
The study, published in The Lancet, represents a medical milestone, having achieved what no study had previously achieved: a gene therapy that has managed to cure Fanconi anemia.
The authors are a team of Spanish researchers who have treated patients with subtype A of this disease, caused by mutations in the FANCA gene.
In the study they have shown that autotransfusion of stem cells with the corrected genetic defect facilitates an increase in the number of corrected cells in patients.
The Phase I/II clinical trial was promoted by the Foundation of Hospital Infantil Universitario Niño Jesús in Madrid and the long-term follow-up trial was sponsored by Rocket Pharmaceuticals.
The principal investigators of the study are hematologists from the Advanced Therapies Unit of the Hospital Infantil Universitario Niño Jesús in Madrid and members of the Biomedical Network Research Center for Rare Diseases (CIBERER).
Until now, the therapy used to treat Fanconi anemia was a bone marrow transplant from a donor compatible with the patient, which entailed certain risks, such as having to undergo chemotherapy treatment prior to the transplant.
In the current trial, after obtaining stem cells from the patient himself, they were genetically edited to correct the mutation responsible for the disease, using a genetically modified virus. After the editing process, the cells already free of the genetic defect were transfused to the patient.
After a seven-year follow-up, the infusion of corrected stem cells from the patient himself has managed to increase his healthy cells, in some cases up to 90%.
In the case of patients with Fanconi anemia, obtaining and manipulating cells ex vivo are very complex processes, given that their stem cells are very fragile and have defects in their ability to divide. For this reason, despite the numerous studies previously carried out in the United States, no effective gene therapy had been achieved in these cases.
The first preclinical studies were carried out in the CIEMAT Biomedical Research Unit in 2002, and work was then carried out to develop the therapeutic vector. After demonstrating its efficacy in correcting the defect in patients’ stem cells in experimental in vivo models, clinical studies began.
Rocket Pharmaceuticals is in the process of obtaining authorization to market this therapy from the European Medicines Agency and the Food and Drug Administration.
Other cases
Thirty-six years have passed since the first transplant performed using umbilical cord stem cells to cure a child suffering from Fanconi anemia in France. Since then, more than 30,000 transplants have been performed using this type of cells.
Also in Spain, in 2023, a child was born who had been selected in the embryonic stage to help cure the serious hereditary disease of his older brother.
The little boy suffered from a serious genetic disease called sickle cell anemia, which he was diagnosed with when he was just six months old. This rare disease affects the production of hemoglobin, the protein responsible for transporting oxygen to all the tissues of the body.
Bioethical assessment
The success achieved now by applying gene therapy to affected cells of patients with Fanconi anemia constitutes a significant advance in the application of gene editing in clinical therapies.
This therapy successfully corrects the mutation responsible for the disease and allows the treated cells to proliferate in their bone marrows.
Other attempts to address this type of disease present bioethical difficulties, such as the generation of histocompatible siblings through in vitro fertilization, so that they could serve as donors for their sick siblings after their birth.
The so-called “designer babies” represent an instrumentalization of the embryos generated to be used in future therapies, in addition to offering low efficiency.
In the case of the Nash siblings, the theoretical statistical probability of obtaining a healthy embryo was 2.5%, that is, 40 embryos were needed to obtain 1 that would result in a successful pregnancy.
Furthermore, the process took 4.5 years, including IVF, preimplantation diagnosis and pregnancy. The average cost per cycle was around $20,000.
In the case of the trial we are now discussing, the use of the patient’s own cells eliminates the risks associated with immunological rejection of any transplant. The genetic treatment that has now proved effective allows the corrected cells to be transfused, which proliferate in the patient, curing the disease.
Gene editing used to treat mutations responsible for previously incurable diseases opens up a horizon of hope for addressing pathologies for which there is no therapeutic alternative.
Controlling the unwanted effects of gene editing, safety in its application, increasing its efficacy and reducing costs are the challenges that researchers in this promising field must face.

Julio Tudela and Ester Bosch
Bioethics Observatory – Institute of Life Sciences
Catholic University of Valencia